<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24183115</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ene, Gabriela</dc:author>
<dc:author>Vidal, Rosa</dc:author>
<dc:author>Llamas Sillero, M Pilar</dc:author>
<dc:author>Miranda, Carolina</dc:author>
<dc:author>García Raso, Aránzazu</dc:author>
<dc:author>Mata, Raquel</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVE Venous and arterial thrombosis, despite being historically considered as distinct conditions, share certain risk factors. Dyslipidemia is a clinical condition with a relatively high prevalence in the population and has been associated with an increased thrombotic risk. Lipids and lipoproteins modulate the expression and/or function of thrombotic, fibrinolytic and rheological factors. PATIENTS AND METHOD We have developed a descriptive, retrospective, comparative, cross-sectional study including a group of 313 patients with venous thromboembolism (VTE). We collected basic demographic data, cardiovascular risk factors and thrombotic complications. All patients were subjected to a lipid profile study with determination of total cholesterol, high density lipoprotein cholesterol (cHDL), low density lipoprotein cholesterol (cLDL) and triglycerides. RESULTS The multivariable analysis showed that dyslipidemia was a risk factor for VTE (odds ratio [OR] 3.87, 95% confidence interval [95% CI] 2.72-5.56; P&lt;.0001). Of a total of 313 patients included in the study, 31% (n=97) had a recurrent thrombotic event and 23% (n=72) developed post-thrombotic syndrome. cHDL levels below 35 mg/dl and cLDL levels higher than 180 mg/dl represented risk factors for the development of recurrent thrombosis, OR 3.12 (95% CI 1.35-7.74; P=.008) and OR 2.35 (95% CI 1.24-4.45; P=.008), respectively, and post-thrombotic syndrome, OR 3.44 (95% CI 1.43-8.83; P=.005) and OR 2.35 (95% CI 1.24-4.45; P=.008). CONCLUSIONS Our study confirmed the association between dyslipidemia and VTE and showed a risk of thrombosis nearly 4 times higher in individuals with this disease. In addition, alterations in the lipid profile were also related to a higher prevalence of thrombotic complications, recurrence and post-thrombotic syndrome.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:subject>Colesterol unido a lipoproteínas de baja densidad</dc:subject>
<dc:subject>High density lipoprotein cholesterol</dc:subject>
<dc:subject>Colesterol unido a lipoproteínas de alta densidad</dc:subject>
<dc:subject>Enfermedad tromboembólica venosa</dc:subject>
<dc:subject>Low density lipoprotein cholesterol</dc:subject>
<dc:subject>Lipid profile</dc:subject>
<dc:subject>Venous thromboembolism</dc:subject>
<dc:subject>Perfil lipídico</dc:subject>
<dc:date>2014 Jul 07 </dc:date>
<dc:title xml:lang="es">Asociación entre enfermedad tromboembólica venosa y dislipidemia.</dc:title>
<dc:title xml:lang="en">[Association between venous thrombosis and dyslipidemia].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
